Henry H. Ji Ph.D.
Net Worth

Last updated:

What is Henry H. Ji Ph.D. net worth?

The estimated net worth of Dr. Henry H. Ji Ph.D. is at least $22,751,100 as of 7 Sep 2022. He has earned $1,100 from insider trading and has received compensation worth at least $22,750,000 in Sorrento Therapeutics, Inc..

What is the salary of Henry H. Ji Ph.D.?

Dr. Henry H. Ji Ph.D. salary is $1,750,000 per year as Chairman, Pres & Chief Executive Officer in Sorrento Therapeutics, Inc..

How old is Henry H. Ji Ph.D.?

Dr. Henry H. Ji Ph.D. is 61 years old, born in 1964.

What stocks does Henry H. Ji Ph.D. currently own?

As insider, Dr. Henry H. Ji Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Sorrento Therapeutics, Inc. (SRNE) Chairman, Pres & Chief Executive Officer 129 $0 $0

What does Sorrento Therapeutics, Inc. do?

Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.

SRNE logo
SRNE
Sorrento Therapeutics, Inc.
$0

Henry H. Ji Ph.D. insider trading

Sorrento Therapeutics, Inc.

Dr. Henry H. Ji Ph.D. has made only one insider trade between 2012-2022, according to the Form 4 filled with the SEC. He purchased 129 units of SRNE stock worth $1,548 on 7 Sep 2022.

As of 7 Sep 2022 he still owns at least 129 units of SRNE stock.

Transaction Date Security Shares Price per share Total value Source
Purchase
Call Option (right to buy) 129 $12 $1,548
Purchase
Common Stock 88,888 $2.02 $179,376
Purchase
Call Option (right to buy) 759 $12 $9,108
Purchase
Common Stock 55,555 $1.96 $108,888
Purchase
Common Stock 33,333 $2.11 $70,333
Sale
Put Option (obligation to buy) 200 $5.5 $1,100
Purchase
Call Option (right to buy) 1,000 $15 $15,000
Purchase
Common Stock 22,222 $2.06 $45,777
Purchase
Common Stock 10,000 $1.4 $14,000
Option
Common Stock 10,000 $4 $40,000
Option
Non-qualified stock options 10,000 $4 $40,000
Option
Common Stock 12,000 $1.75 $21,000
Option
Common Stock 6,000 $1.75 $10,500
Purchase
Common Stock 64,600 $9.95 $642,770
Purchase
Common Stock 1,801,801 N/A N/A
Purchase
Common Stock Warrant (right to buy) 261,438 N/A N/A
Purchase
Common Stock 29,001 N/A N/A
Purchase
Common Stock 100,000 N/A N/A
Purchase
Common Stock 2,000 N/A N/A
Purchase
Common Stock 20,000 N/A N/A
Purchase
Common Stock 20,000 N/A N/A
Purchase
SRNE 35 March 2016 Call Options 500 N/A N/A
Purchase
Common Stock 8,888 N/A N/A
Purchase
Common Stock 8,888 N/A N/A
Purchase
Common Stock 5,999 N/A N/A
Purchase
Common Stock 4,000 N/A N/A
Purchase
Common Stock 3,000 N/A N/A
Purchase
Common Stock 1,000 N/A N/A
Purchase
Common Stock 1,000 N/A N/A
Purchase
Common Stock 1,000 N/A N/A
Purchase
Common Stock 2,000 N/A N/A
Purchase
Common Stock 6,250,000 N/A N/A

Sorrento Therapeutics key executives

Sorrento Therapeutics, Inc. executives and other stock owners filed with the SEC: